We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Merge Healthcare and Cato Research Establish New Five–Year e-Trials Technology Transfer Agreement

By LabMedica International staff writers
Posted on 17 Jun 2010
Merge Healthcare (Milwaukee, WI, USA), a health information technology (IT) solutions provider, reported that it was selected by Cato Research, Ltd. More...
(Durham, NC, USA) to provide the proprietary etrials EDC solution through Merge's technology transfer program. This new agreement expands Merge's partnership with Cato to provide additional technology for clinical trials management, as well as extending the relationship for an additional five years.

"We have enjoyed a long-standing partnership with Merge Healthcare for their clinical trial solutions," noted Allen Cato, M.D., Ph.D., and CEO of Cato Research, Ltd. "The etrials technology has been consistent and intuitive, and the Merge team has been quick to help us use it successfully. Adding the etrials EDC platform in a technology transfer model will enable our company to efficiently build and deliver solutions to help our customers run cost-effective clinical studies."

The technology transfer program allows Cato to use the etrials EDC system to build and deploy custom clinical trial studies that leverage the powerful reporting capabilities of Merge's technology. Because the etrials EDC solution is built on a SaaS platform, it can be licensed on a subscription or study basis. Moreover, Merge's etrials IVR and ePRO solutions can be integrated with the EDC system to provide comprehensive eClinical solutions. Merge's team of clinical trial experts will also provide training and support to Cato.

"We are thrilled to partner with Cato to bring etrials EDC into their portfolio of clinical trial solutions," said Justin Dearborn, Merge's chief executive officer. "With our robust EDC offering, Cato will be able to deliver an easy-to-use solution to their clients. It is our goal to understand how our customers' conduct business in order to deliver robust solutions that meet their long-term needs and allow for mutually beneficial partnerships like this one."

Merge Healthcare develops and integrates information technology to create a better electronic healthcare experience. Merge products range from standards-based development toolkits to advanced clinical applications.

Cato is a global contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, medical device, and medical diagnostic industries. Cato's services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval.

Related Links:
Merge Healthcare
Cato Research


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.